argenx SE (NASDAQ:ARGX) Shares Sold by Values First Advisors Inc.

Values First Advisors Inc. cut its holdings in shares of argenx SE (NASDAQ:ARGX) by 12.1% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 1,049 shares of the company’s stock after selling 145 shares during the quarter. Values First Advisors Inc.’s holdings in argenx were worth $645,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. Ritholtz Wealth Management acquired a new stake in argenx in the 3rd quarter valued at about $262,000. Creative Planning increased its stake in shares of argenx by 54.1% during the third quarter. Creative Planning now owns 5,437 shares of the company’s stock worth $2,947,000 after buying an additional 1,909 shares during the period. Aaron Wealth Advisors LLC acquired a new stake in argenx in the third quarter valued at approximately $241,000. Blue Trust Inc. lifted its stake in argenx by 413.9% in the third quarter. Blue Trust Inc. now owns 370 shares of the company’s stock worth $201,000 after acquiring an additional 298 shares during the last quarter. Finally, Signaturefd LLC grew its holdings in argenx by 17.3% during the 3rd quarter. Signaturefd LLC now owns 1,637 shares of the company’s stock worth $887,000 after acquiring an additional 242 shares in the last quarter. Hedge funds and other institutional investors own 60.32% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have recently weighed in on ARGX. Guggenheim raised their price objective on shares of argenx from $585.00 to $665.00 and gave the company a “buy” rating in a report on Friday, November 1st. HC Wainwright restated a “buy” rating and issued a $717.00 price target (up from $670.00) on shares of argenx in a research note on Tuesday, January 14th. Deutsche Bank Aktiengesellschaft downgraded argenx from a “hold” rating to a “sell” rating in a report on Friday, January 17th. Truist Financial reiterated a “buy” rating and issued a $700.00 price objective (up previously from $660.00) on shares of argenx in a report on Tuesday, January 14th. Finally, JPMorgan Chase & Co. boosted their target price on argenx from $640.00 to $670.00 and gave the stock an “overweight” rating in a research note on Monday, November 4th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating, eighteen have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $658.39.

argenx Price Performance

Shares of NASDAQ:ARGX opened at $649.09 on Thursday. argenx SE has a 1-year low of $349.86 and a 1-year high of $678.21. The stock has a market cap of $39.44 billion, a P/E ratio of -737.60 and a beta of 0.58. The firm has a fifty day moving average price of $638.76 and a 200 day moving average price of $580.34.

argenx Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.